Manikya Bhasma as Nanomedicine for Cancer Cells Treatment and its Characterization Using Modern Scientific Tools
DOI:
https://doi.org/10.31557/apjec.2024.7.1.47-55Keywords:
Manikya Bhasma, Nanomedicine, lung cancer cells (A-547), breast cancer cells (MCF-7)Abstract
Objective: This study is focused on evaluating the safety and effectiveness of Manikya Bhasma, an Ayurvedic preparation, as a nanomedicine for cancer treatment, and exploring its potential therapeutic properties using modern scientific tools.
Methods: Manikya Bhasma, composed of purified ruby, orpiment, and arsenic sulfide, was analyzed using XRD (X-ray Diffraction) for crystallite size determination, FESEM (Field Emission Scanning Electron Microscopy) for morphological analysis, EDS (Energy Dispersive X-ray spectroscopy) for elemental composition, and FTIR (Fourier Transform Infrared Spectroscopy) for functional group identification. The anticancer activity of Manikya Bhasma nanoparticles was assessed against breast cancer (MCF-7) and lung cancer (A-547) cell lines at varying concentrations (0-1000 µg/mL).
Results: The XRD analysis revealed an average crystallite size of 60 nm. FESEM micrographs confirmed the uniform distribution of particles within the sample. Notably, Manikya Bhasma demonstrated a clear dose-dependent anticancer activity against both MCF-7 and A-547 cell lines, providing reassurance about its potential effectiveness.
Conclusion: This study suggests that Manikya Bhasma has the potential to be a promising nanomedicine for cancer treatment, highlighting the therapeutic relevance of traditional Ayurvedic medicine in modern scientific research. This research serves as a bridge between traditional and modern approaches, offering new insights into the application of Ayurvedic formulations in contemporary medicine.




3.jpg)



